Skip to main
KYTX

KYTX Stock Forecast & Price Target

KYTX Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kyverna Therapeutics Inc. is gaining substantial credibility in the biopharmaceutical sector with its innovative cell therapy products, specifically KYV-101 and KYV-201, targeting autoimmune diseases. Recent data from key opinion leaders (KOLs) has elevated the probability of approval for KYV-101 in myasthenia gravis (MG) to 35%, reflecting enhanced confidence in its performance and safety, as well as its strong clinical responses in compassionate-use scenarios. Additionally, the promising efficacy of KYV-101 compared to traditional treatments, such as rituximab, reinforces its potential as a leading therapeutic option across multiple indications within immunology and inflammatory diseases.

Bears say

Kyverna Therapeutics Inc's stock outlook is negatively impacted by several fundamental risks associated with its product candidates. The potential lack of durable responses in patients treated with KYV-101 for conditions such as lupus nephritis (LN) and myasthenia gravis (MG) raises concerns about the efficacy and long-term viability of the therapy, especially as data matures. Additionally, the company faces the risk of failing to generate positive results for KYV-101 in a third indication, systemic lupus erythematosus (SPS), alongside the looming threat of long-term dilution that may affect shareholder value.

KYTX has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kyverna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kyverna Therapeutics Inc (KYTX) Forecast

Analysts have given KYTX a Buy based on their latest research and market trends.

According to 3 analysts, KYTX has a Buy consensus rating as of Jan 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kyverna Therapeutics Inc (KYTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.